Literature DB >> 21358287

Emerging antibody products and Nicotiana manufacturing.

Kevin J Whaley1, Andrew Hiatt, Larry Zeitlin.   

Abstract

Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.

Mesh：

Substances：

Year:  2011        PMID： 21358287      PMCID： PMC3166493          DOI： 10.4161/hv.7.3.14266

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  61 in total

1.  Diffusion of macromolecules and virus-like particles in human cervical mucus.

Authors:  S S Olmsted; J L Padgett; A I Yudin; K J Whaley; T R Moench; R A Cone
Journal:  Biophys J       Date:  2001-10       Impact factor: 4.033

2.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

3.  Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.

Authors:  Irmgard Roeckl-Wiedmann; Johannes G Liese; Eva Grill; Birgit Fischer; David Carr; Bernd H Belohradsky
Journal:  Eur J Pediatr       Date:  2003-02-06       Impact factor: 3.183

4.  Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo.

Authors:  Armelle Phalipon; Ana Cardona; Jean Pierre Kraehenbuhl; Léna Edelman; Philippe J Sansonetti; Blaise Corthésy
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

Review 5.  Optimal and consistent protein glycosylation in mammalian cell culture.

Authors:  Patrick Hossler; Sarwat F Khattak; Zheng Jian Li
Journal:  Glycobiology       Date:  2009-06-03       Impact factor: 4.313

6.  Production of antibodies in transgenic plants.

Authors:  A Hiatt; R Cafferkey; K Bowdish
Journal:  Nature       Date:  1989-11-02       Impact factor: 49.962

7.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

8.  Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease.

Authors:  Pierre Bruhns; Astrid Samuelsson; Jeffrey W Pollard; Jeffrey V Ravetch
Journal:  Immunity       Date:  2003-04       Impact factor: 31.745

9.  Epitopes involved in antibody-mediated protection from Ebola virus.

Authors:  J A Wilson; M Hevey; R Bakken; S Guest; M Bray; A L Schmaljohn; M K Hart
Journal:  Science       Date:  2000-03-03       Impact factor: 47.728

10.  Cost-effectiveness of palivizumab in New Zealand.

Authors:  A M Vogel; M J McKinlay; T Ashton; D R Lennon; J E Harding; R Pinnock; D Graham; K Grimwood; P K Pattemore; M Schousboe
Journal:  J Paediatr Child Health       Date:  2002-08       Impact factor: 1.954
View more
  28 in total

1.  Non-Antiretroviral Microbicides for HIV Prevention.

Authors:  Yanille Scott; Charlene S Dezzutti
Journal:  AIDS Rev       Date:  2016 Jul-Sep       Impact factor: 2.500

2.  Chimeric plantibody passively protects mice against aerosolized ricin challenge.

Authors:  Erin K Sully; Kevin J Whaley; Natasha Bohorova; Ognian Bohorov; Charles Goodman; Do H Kim; Michael H Pauly; Jesus Velasco; Ernie Hiatt; Josh Morton; Kelsi Swope; Chad J Roy; Larry Zeitlin; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

3.  Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide.

Authors:  Kara J Levinson; Samantha R Giffen; Michael H Pauly; Do H Kim; Ognian Bohorov; Natasha Bohorova; Kevin J Whaley; Larry Zeitlin; Nicholas J Mantis
Journal:  J Immunol Methods       Date:  2015-04-09       Impact factor: 2.303

4.  Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit.

Authors:  Joanne M O'Hara; Kevin Whaley; Michael Pauly; Larry Zeitlin; Nicholas J Mantis
Journal:  Vaccine       Date:  2011-12-22       Impact factor: 3.641

5.  Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.

Authors:  Andrew Hiatt; Natasha Bohorova; Ognian Bohorov; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; Kevin J Whaley; Pedro A Piedra; Brian E Gilbert; Larry Zeitlin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

Review 6.  Strategies for preventing mucosal cell-associated HIV transmission.

Authors:  Kevin J Whaley; Kenneth H Mayer
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

7.  Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo.

Authors:  Yanille M Scott; Seo Young Park; Charlene S Dezzutti
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

8.  Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in Mucus.

Authors:  Timothy Wessler; Alex Chen; Scott A McKinley; Richard Cone; Gregory Forest; Samuel K Lai
Journal:  ACS Infect Dis       Date:  2015-10-17       Impact factor: 5.084

9.  Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Authors:  Krystal Teasley Hamorsky; Tiffany W Grooms-Williams; Adam S Husk; Lauren J Bennett; Kenneth E Palmer; Nobuyuki Matoba
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

10.  Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.

Authors:  Jose Condori; Walter Acosta; Jorge Ayala; Varun Katta; Ashley Flory; Reid Martin; Jonathan Radin; Carole L Cramer; David N Radin
Journal:  Mol Genet Metab       Date:  2015-12-08       Impact factor: 4.797
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.